Nivolumab Plus Chemotherapy Continues to Demonstrate Long-Term Survival Benefits in Patients with Gastric, GEJ and Oesophageal Adenocarcinoma By Ogkologos - February 24, 2026 210 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from 5 years of follow-up of CheckMate 649 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Radiation-Induced ‘Genomic Scars’ Associate with Poor Patient Outcome October 9, 2020 Perioperative Treatment with Nivolumab Results in Significantly Longer Event-Free Survival than... May 22, 2024 ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the... June 12, 2026 Prescribing Exercise as Cancer Treatment: A Conversation with Dr. Kathryn Schmitz November 12, 2019 Load more HOT NEWS Patritumab Deruxtecan Demonstrates a Manageable Safety Profile and Durable Efficacy in... Pregnant Mom Experiencing Severe Leg And Back Pain Diagnosed With Stage... FDA Approves Safety Labelling Changes Regarding DPD Deficiency for Fluorouracil Injection... Inavolisib Plus Palbociclib-Fulvestrant Prolongs OS in Patients with PIK3CA-Mutated Advanced Breast Cancer
